Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study

BACKGROUND: Previous analysis of the study (NCT02577393) had demonstrated the application of epigallocatechin-3-gallate (EGCG) could be safe and effective in the prevention and treatment of acute radiation esophagitis in patients with advanced lung cancer. EGCG seemed to improve the response rate of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wanqi, Zhao, Yalan, Zhang, Shuyu, Li, Xiaolin, Xing, Ligang, Zhao, Hanxi, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223749/
https://www.ncbi.nlm.nih.gov/pubmed/34178681
http://dx.doi.org/10.3389/fonc.2021.686950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223749/
https://www.ncbi.nlm.nih.gov/pubmed/34178681
http://dx.doi.org/10.3389/fonc.2021.686950

Ejemplares similares